Cellectis S.A. ADR (CLLS) Stock Price, Quote & News

Company Profile

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 1 81 69 16 00

Website: www.cellectis.com

Address:

8, rue de la Croix Jarry, Paris, France

rlkloehn Mar. 9 at 4:39 PM

$CLLS The 28th annual Barclays Global Healthcare conference will be held from March 10 to 12, 2026 in Miami, FL. Arthur Stril, Chief Financial Officer and Chief Business Officer, will participate in informal discussions on March 11, 2026 at 10:00 AM ET. He will also hold appointments with investors.

0 · Reply

rlkloehn Mar. 9 at 4:38 PM

$CLLS The Citizens Life Sciences 2026 conference will be held on March 10 and 11, 2026 in Miami Beach, United States. André Choulika, General Manager, and Arthur Stril, Chief Financial Officer and Sales Director of Cellectis, will be present. They will participate in an informal discussion on March 11, 2026 at 4:35 p.m. (Eastern Time) and hold meetings with investors.

0 · Reply

focafoca99 Mar. 4 at 11:33 PM

$CLLS published monthly capital data: 100,590,994 shares and 105,825,561 voting rights as of Feb 28, so the structure update is very explicit.

0 · Reply

OfficialStocktwitsUser Feb. 23 at 11:48 PM

$CLLS RSI: 53.65, MACD: -0.0803 Vol: 0.22, MA20: 3.82, MA50: 4.23 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BillionerOfKing Feb. 18 at 11:37 PM

$CLLS Current Stock Price: $4.05 Contracts to trade: $5.0 CLLS Feb 20 2026 Call Entry: $0.05 Exit: $0.06 ROI: 27% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

ChartVader Feb. 17 at 8:49 AM

$CLLS Pre-revenue biotech; early-stage

0 · Reply

NathanielBanuelos885 Feb. 11 at 2:54 PM

$CLLS Cellectis; gene-editing biotech; allogeneic CAR-T; clinical setbacks, cash burn, technology is promising but manufacturing challenges persist.

1 · Reply

finedge Feb. 9 at 3:57 PM

$CLLS let’s go!

0 · Reply

GJ_Rockabilt Feb. 2 at 2:20 PM

$TPST $CLLS $AZN Let the Bidding WAR begin!

0 · Reply

BillionerOfKing Jan. 20 at 1:42 AM

$CLLS Current Stock Price: $4.07 Contracts to trade: $5 CLLS Feb 20 2026 Call Entry: $0.10 Exit: $0.13 ROI: 29% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Monthly information on share capital and company voting rights

Mon, 05 Jan 2026 16:30:00 -0500 - 2 months ago

Monthly information on share capital and company voting rights

2025-12-23T18:30:18.000Z - 2 months ago

Cellectis (CLLS) Receives New 'Buy' Rating from Clear Street | CLLS Stock News

2025-12-18T13:52:35.000Z - 2 months ago

Cellectis: Showcasing Encouraging Data, But Still Early To Make A Run Like This

2025-12-16T18:09:18.000Z - 3 months ago

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday

Tue, 16 Dec 2025 13:09:18 -0500 - 3 months ago

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday

Mon, 15 Dec 2025 17:39:00 -0500 - 3 months ago

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

2025-12-15T22:25:36.000Z - 3 months ago

Cellectis (CLLS) Arbitration Outcome Adjusts License Agreement

Mon, 15 Dec 2025 16:51:00 -0500 - 3 months ago

Cellectis Announces Arbitral Decision in Dispute with Servier

Thu, 11 Dec 2025 21:31:37 -0500 - 3 months ago

Cellectis' Allogeneic CAR-T Potential Still Justifies A 'Buy'

Mon, 08 Dec 2025 01:30:00 -0500 - 3 months ago

ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL

Wed, 03 Dec 2025 16:30:00 -0500 - 3 months ago

Monthly information on share capital and company voting rights

Wed, 19 Nov 2025 06:18:00 -0500 - 4 months ago

Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells

2025-11-12T16:12:50.000Z - 4 months ago

Cellectis Q3 2025 Earnings Preview

2025-11-07T21:50:35.000Z - 4 months ago

Cellectis (CLLS) Reports Strong Q3 Revenue Growth and Promising Clinical Data

2025-11-07T21:45:30.000Z - 4 months ago

Cellectis GAAP EPS of $0.01 beats by $0.24, revenue of $37.16M

Fri, 07 Nov 2025 16:30:00 -0500 - 4 months ago

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-11-06T18:03:22.000Z - 4 months ago

Cellectis Earnings Preview

2025-11-03T15:02:27.000Z - 4 months ago

Cellectis (CLLS) to Present Key Research at 2025 ASH Meeting

Mon, 03 Nov 2025 09:15:00 -0500 - 4 months ago

Cellectis to Present a Development Update for eti-cel at ASH 2025

Fri, 31 Oct 2025 16:30:00 -0400 - 4 months ago

Cellectis to Report Third Quarter Financial Results on November 7, 2025

2025-10-17T15:01:15.000Z - 5 months ago

CLLS: Analyst Raises Price Target Significantly for Cellectis | CLLS Stock News

Thu, 16 Oct 2025 15:19:00 -0400 - 5 months ago

Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL

Thu, 16 Oct 2025 08:46:20 -0400 - 5 months ago

Top 2 Health Care Stocks That May Keep You Up At Night This Month

Thu, 16 Oct 2025 07:00:00 -0400 - 5 months ago

Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers

2025-10-14T14:25:33.000Z - 5 months ago

Allogene licensor Cellectis faces patent lawsuit in the U.S.

Tue, 07 Oct 2025 02:40:00 -0400 - 5 months ago

Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress

2025-08-28T11:19:00.000Z - 6 months ago

Top 5 Biotech Stocks With Strong Momentum

Tue, 05 Aug 2025 11:50:31 -0400 - 7 months ago

Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript

2025-08-04T20:50:24.000Z - 7 months ago

Cellectis GAAP EPS of -$0.24 misses by $0.03, revenue of $16M beats by $4.36M

Mon, 04 Aug 2025 16:30:00 -0400 - 7 months ago

Cellectis Reports Second Quarter 2025 Financial Results & Business Updates

2025-08-04T08:32:29.000Z - 7 months ago

Earnings Scheduled For August 4, 2025

2025-08-01T21:35:39.000Z - 7 months ago

Cellectis Q2 2025 Earnings Preview

Mon, 28 Jul 2025 16:30:00 -0400 - 8 months ago

Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025

2025-07-02T20:31:06.000Z - 9 months ago

Cellectis files $200M mixed shelf offering

Thu, 26 Jun 2025 16:30:00 -0400 - 9 months ago

Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025

Wed, 21 May 2025 16:30:00 -0400 - 10 months ago

Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025

2025-05-15T14:58:09.000Z - 10 months ago

Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy

2025-05-12T21:08:54.000Z - 10 months ago

Cellectis Non-GAAP EPS of -$0.17, revenue of $12M misses by $1.83M

Mon, 12 May 2025 16:30:00 -0400 - 10 months ago

Cellectis Reports Financial Results for the First Quarter 2025

2025-05-09T17:02:32.000Z - 10 months ago

Cellectis Q1 2025 Earnings Preview

Tue, 06 May 2025 16:30:00 -0400 - 11 months ago

Cellectis to Report First Quarter Financial Results on May 12, 2025

Mon, 28 Apr 2025 16:30:00 -0400 - 11 months ago

Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting

Fri, 14 Mar 2025 10:36:24 -0400 - 1 year ago

Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript

2025-03-14T09:08:31.000Z - 1 year ago

Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

2025-03-14T04:53:35.000Z - 1 year ago

Cellectis Non-GAAP EPS of -$0.16 beats by $0.05, revenue of $33.22M beats by $23.63M

Thu, 13 Mar 2025 18:07:00 -0400 - 1 year ago

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

Fri, 07 Mar 2025 16:30:00 -0500 - 1 year ago

Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025

Mon, 24 Feb 2025 01:30:00 -0500 - 1 year ago

Cellectis Presents ‘Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025

2025-02-24T06:30:00.000Z - 1 year ago

Cellectis Presents 'Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025

Dec 12, 2024, 3:08 PM EST - 1 year ago

Cellectis: Poised To Start Answering Questions In 2025

Dec 10, 2024, 4:30 PM EST - 1 year ago

Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)

Nov 5, 2024, 4:30 PM EST - 1 year ago

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

Nov 5, 2024, 1:59 PM EST - 1 year ago

Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:30 PM EST - 1 year ago

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

Oct 22, 2024, 2:00 AM EDT - 1 year ago

Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress

Sep 3, 2024, 4:30 PM EDT - 1 year ago

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

Aug 30, 2024, 10:25 AM EDT - 1 year ago

Cellectis: Cheap With Promising But Speculative Cancer Therapies

Aug 26, 2024, 4:30 PM EDT - 1 year ago

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

Aug 7, 2024, 2:00 AM EDT - 1 year ago

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Cellectis Provides Financial Results for the Second Quarter 2024

Aug 1, 2024, 4:30 PM EDT - 1 year ago

FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment

Jul 25, 2024, 4:30 PM EDT - 1 year ago

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

Jun 28, 2024, 4:30 PM EDT - 1 year ago

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

Jun 20, 2024, 4:30 PM EDT - 1 year ago

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

Jun 12, 2024, 4:30 PM EDT - 1 year ago

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Jun 4, 2024, 4:30 PM EDT - 1 year ago

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

May 30, 2024, 2:06 PM EDT - 1 year ago

Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript

May 30, 2024, 9:14 AM EDT - 1 year ago

Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024

May 29, 2024, 4:30 PM EDT - 1 year ago

Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024

May 28, 2024, 4:30 PM EDT - 1 year ago

Cellectis Reports Financial Results for First Quarter 2024

May 27, 2024, 4:30 PM EDT - 1 year ago

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

rlkloehn Mar. 9 at 4:39 PM

0 · Reply

rlkloehn Mar. 9 at 4:38 PM

0 · Reply

focafoca99 Mar. 4 at 11:33 PM

$CLLS published monthly capital data: 100,590,994 shares and 105,825,561 voting rights as of Feb 28, so the structure update is very explicit.

0 · Reply

OfficialStocktwitsUser Feb. 23 at 11:48 PM

0 · Reply

BillionerOfKing Feb. 18 at 11:37 PM

0 · Reply

ChartVader Feb. 17 at 8:49 AM

$CLLS Pre-revenue biotech; early-stage

0 · Reply

NathanielBanuelos885 Feb. 11 at 2:54 PM

$CLLS Cellectis; gene-editing biotech; allogeneic CAR-T; clinical setbacks, cash burn, technology is promising but manufacturing challenges persist.

1 · Reply

finedge Feb. 9 at 3:57 PM

$CLLS let’s go!

0 · Reply

GJ_Rockabilt Feb. 2 at 2:20 PM

$TPST $CLLS $AZN Let the Bidding WAR begin!

0 · Reply

BillionerOfKing Jan. 20 at 1:42 AM

0 · Reply

rlkloehn Jan. 8 at 10:29 PM

$CLLS https://markets.businessinsider.com/news/stocks/cellectis-announces-2026-strategy-and-catalysts-1035696727?op=1

1 · Reply

PennyScam Dec. 30 at 9:49 PM

$CLLS I want what your smoking Isle in the west. Money is money. From where Im from, you take whats given to you. Capish. Institutions are great but not needed. The fact that AZ took common control as lead investor is now presently funding everything while allowing people of all creed, race and colour to join in at the very bottom. To me thats just being overly kind. I am Long here. Not invested now and I hold no position but maybe someday I will be. It looks promising. Im actually not interested in Cellectis one bit. I do like Astra. My brain can’t understand or pronounce this crazy tech lingo. Too old. Too crazy. I seriously respect this arena. This russian guy is pretty slick. I just want more AZ. Its simple. I think all roads here lead to the top. 🙏🤞🏻🍻Crazy K

0 · Reply

IsletInvest Dec. 27 at 4:57 AM

$CLLS Investor attention is skewing toward repeatable operating performance instead of aspirational projections. Forecast reliability has room to improve materially. Predictability would attract a deeper institutional audience. Investors will likely insist on proof before expanding exposure.

0 · Reply

ECommerceEric Dec. 24 at 11:15 AM

$CLLS Risk-adjusted upside exists only if progress validates the underlying thesis beyond narrative appeal. Delays or dilution could materially reshape the risk profile.

0 · Reply

JarvisFlow Dec. 23 at 10:03 AM

Clear Street updates rating for Cellectis ( $CLLS ) to Buy, target set at 9.

0 · Reply

mikefbi Dec. 23 at 2:14 AM

$CLLS Another great day

0 · Reply

mikefbi Dec. 22 at 3:17 PM

$CLLS Going Higher

0 · Reply

Jay_Bingo Dec. 16 at 9:44 PM

$CLLS It is a matter not if but when, this will be another Bellicum.

0 · Reply

mikefbi Dec. 16 at 6:01 PM

$CLLS Replacing some of the shares sold earlier

0 · Reply

DARKP00L Dec. 16 at 2:39 PM

$CLLS 09:14 on Dec. 16 2025 Cellectis shares are trading lower after arbitration ruled in favor of Allogene in relation to cemacabtagene ansegedleucel. #tradeideas

0 · Reply

SuperGreenToday Dec. 15 at 2:54 PM

$CLLS Share Price: $4.57 Contract Selected: May 15, 2026 $5 Calls Buy Zone: $0.80 – $0.98 Target Zone: $1.30 – $1.59 Potential Upside: 54% ROI Time to Expiration: 150 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Market Cap	212.32M
Revenue (ttm)	49.22M
Net Income (ttm)	-36.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-74.69%
Debt to Equity Ratio	0.81

Volume	30,400
Avg Vol	47,530
Day's Range	N/A - N/A
Shares Out	55.58M
Stochastic %K	55%
Beta	2.85
Analysts	Strong Sell
Price Target	$7.67